- Home
- LEXX vs LPCN Comparison
LEXX vs LPCN Comparison
Compare LEXX & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- LPCN
- Stock Information
- Founded
- LEXX 2004
- LPCN 1997
- Country
- LEXX Canada
- LPCN United States
- Employees
- LEXX N/A
- LPCN N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- LEXX Health Care
- LPCN Health Care
- Exchange
- LEXX Nasdaq
- LPCN Nasdaq
- Market Cap
- LEXX 19.6M
- LPCN 16.1M
- IPO Year
- LEXX N/A
- LPCN N/A
- Fundamental
- Price
- LEXX $0.95
- LPCN $3.12
- Analyst Decision
- LEXX Strong Buy
- LPCN Strong Buy
- Analyst Count
- LEXX 1
- LPCN 2
- Target Price
- LEXX $5.00
- LPCN $9.00
- AVG Volume (30 Days)
- LEXX 101.8K
- LPCN 33.7K
- Earning Date
- LEXX 07-14-2025
- LPCN 08-07-2025
- Dividend Yield
- LEXX N/A
- LPCN N/A
- EPS Growth
- LEXX N/A
- LPCN N/A
- EPS
- LEXX N/A
- LPCN N/A
- Revenue
- LEXX $615,923.00
- LPCN $3,674,834.00
- Revenue This Year
- LEXX $6.04
- LPCN N/A
- Revenue Next Year
- LEXX $8.36
- LPCN N/A
- P/E Ratio
- LEXX N/A
- LPCN N/A
- Revenue Growth
- LEXX 49.85
- LPCN N/A
- 52 Week Low
- LEXX $0.79
- LPCN $2.68
- 52 Week High
- LEXX $4.38
- LPCN $7.18
- Technical
- Relative Strength Index (RSI)
- LEXX 43.10
- LPCN 49.01
- Support Level
- LEXX $0.79
- LPCN $3.10
- Resistance Level
- LEXX $0.90
- LPCN $3.27
- Average True Range (ATR)
- LEXX 0.04
- LPCN 0.16
- MACD
- LEXX 0.01
- LPCN 0.00
- Stochastic Oscillator
- LEXX 60.87
- LPCN 46.15
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.